Anwita Biosciences and collaborators designed an immune-engaging approach that fuses a checkpoint inhibitor concept with cytokine delivery to address two solid-tumor constraints: inhibitory checkpoints (including LAG-3) and local cytokine limitation. The study describes an IL-2 fusion protein intended to enhance immune checkpoint inhibitor and CAR T responses in solid tumors. The work positions the concept as a way to improve T-cell persistence and activity within tumor microenvironments.